首页> 外文期刊>Heartdrug: excellence in cardiovascular trials >Low-Molecular-Weight Heparin in Acute Coronary Syndromes
【24h】

Low-Molecular-Weight Heparin in Acute Coronary Syndromes

机译:急性冠状动脉综合征的低分子量肝素

获取原文
获取原文并翻译 | 示例
           

摘要

Acute coronary syndrome (ACS) may be divided into two distinct conditions on the basis of the electrographical presence or absence of significant ST-segment elevation. Coronary arterial plaque rupture with subsequent thrombus formation is usually responsible for the development of ACS. A number of antithrombotic therapies have been developed to inhibit key steps in the sequential process of thrombus formation. Thrombin generation is of critical importance in the creation of intracoro-nary thrombosis. Heparins, in therapeutic doses, reduce the risk of death and myocardial infarction by about 50% in aspirin-treated patients presenting with ACS with non-ST-segment elevation. Low-molecular-weight heparin (LMWH) primarily targets the inhibition of factor Xa (and to a lesser extent thrombin) by binding with antithrom-bin. A number of well-designed, large randomized controlled trials have shown that LMWHs have at least comparable efficacy and safety to unfractionated heparin, but their superior practical advantages have made them a mainstay therapy in the treatment of ACS with non-ST-segment elevation. More recently, the role of LMWH in the treatment of ACS with ST elevation has been evaluated in a large randomized trial.
机译:急性冠状动脉综合征(ACS)可以根据具有明显的ST段升高的存在或不存在分为两种不同的条件。随后的血栓形成,冠状动脉菌斑破裂通常是ACS的发展。已经开发了许多抗血栓形成疗法,以抑制血栓形成顺序过程中的关键步骤。凝血酶产生在创建核内血栓形成中至关重要。在治疗剂量的情况下,在接受非ST段升高的ACS的ACS患者中,在治疗剂量的患者中,死亡和心肌梗塞的风险降低了约50%。低分子量肝素(LMWH)主要针对因子Xa(以及较小程度的凝血酶)靶向与抗凝血纤维蛋白的抑制。许多精心设计的大型随机对照试验表明,LMWH至少具有可比性的疗效和安全性,可与未分流的肝素相提并论,但是它们的出色实践优势使它们成为了非ST段升高AC的ACS治疗的主要疗法。最近,在一项大型随机试验中,评估了LMWH在ST升高的ACs治疗中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号